{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:23:16Z","timestamp":1769156596466,"version":"3.49.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Homozygous familial hypercholesterolemia (HoFH) is a rare disorder associated with early atherosclerotic disease due to impairment of the LDL receptor (LDLR) pathway. Because of their molecular defect, current treatment options have limited success in bringing HoFH patient to LDL-C target and morbidity and mortality remain high. We review current and upcoming therapies directed at HoFH, including gene therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent real-world studies have confirmed the strength in lomitapide as a treatment adjunct to statins and other lipid-lowering therapies in HoFH patients. The approval of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitor monoclonal antibodies has also been a welcome addition to the treatment armamentarium offering an additional average reduction in LDL-C levels of 24% when added to background lipid-lowering therapies in this population. Although achieving adequate LDL-C levels in this population is difficult, there are several therapies on the horizon that may help more patients reach goal. Evinacumab, a monoclonal antibody against ANGPTL3, has been shown to substantially reduce LDL-C of an average of 49%, independently of residual LDLR activity. RNA interference targeting PCSK9 and ANGPTL3 shows promise in clinical trials. Adeno-associated virus-mediated gene transfer and gene editing techniques are in early clinical and preclinical development.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>LDL-C lowering in HoFH patients remains very challenging. However, novel treatment options are emerging. Upcoming therapies directed at PCSK9 and ANPTL3 may offer additional LDL-C reduction, to help patients achieve adequate LDL-C levels. Gene therapy and gene editing techniques, if proven effective, may offer a unique opportunity to treat patients with a one-time treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000677","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T07:52:42Z","timestamp":1587628362000},"page":"119-124","source":"Crossref","is-referenced-by-count":15,"title":["Homozygous familial hypercholesterolemia: what treatments are on the horizon?"],"prefix":"10.1097","volume":"31","author":[{"given":"Archna","family":"Bajaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Cuchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MOL.0000000000000179","article-title":"Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives","volume":"26","author":"Sjouke","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart Journal"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.amjcard.2008.07.035","article-title":"Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia","volume":"102","author":"Kolansky","year":"2008","journal-title":"Am J Cardiol"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jacc.2017.06.058","article-title":"Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations","volume":"70","author":"Stein","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.atherosclerosis.2016.03.009","article-title":"Phenotype diversity among patients with homozygous familial hypercholesterolemia: a cohort study","volume":"248","author":"Raal","year":"2016","journal-title":"Atherosclerosis"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3390\/jcm9010219","article-title":"A real-world experience of clinical, biochemical and genetic assessment of patients with homozygous familial hypercholesterolemia","volume":"9","author":"Di Taranto","year":"2020","journal-title":"J Clin Med"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2019.09.006","article-title":"Lipoprotein apheresis efficacy, challenges and outcomes: a descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989\u20132017","volume":"290","author":"Pottle","year":"2019","journal-title":"Atherosclerosis"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacl.2018.05.008","article-title":"Treatment-related and health-related quality of life in lipoprotein apheresis patients","volume":"12","author":"De Gucht","year":"2018","journal-title":"J Clin Lipidol"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term evolocumab in patients with familial hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/ATVBAHA.117.310217","article-title":"Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor): implications for the efficacy of evolocumab","volume":"38","author":"Thedrez","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5551\/jat.45708","article-title":"Safety and efficacy of lomitapide in Japanese patients with homozygous familial hypercholesterolemia (HoFH): results from the AEGR-733-301 Long-Term Extension Study","volume":"26","author":"Nohara","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/2047487319870007","article-title":"Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia","volume":"27","author":"Kolovou","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s12325-017-0531-x","article-title":"Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy","volume":"34","author":"D\u2019Erasmo","year":"2017","journal-title":"Adv Ther"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1007\/s12325-019-00985-8","article-title":"Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia","volume":"36","author":"Ben-Omran","year":"2019","journal-title":"Adv Ther"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol","volume":"39","author":"Thompson","year":"2018","journal-title":"Eur Heart J"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1194\/jlr.M054882","article-title":"Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion","volume":"56","author":"Wang","year":"2015","journal-title":"J Lipid Res"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N Engl J Med"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1161\/ATVBAHA.119.313051","article-title":"Functional analysis of LDLR (low-density lipoprotein receptor) variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity","volume":"39","author":"Banerjee","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","article-title":"Inclisiran: new hope in the management of lipid disorders?","volume":"14","author":"Dyrbu\u015b","year":"2019","journal-title":"J Clin Lipidol"},{"key":"R30-20230917","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.atherosclerosis.2019.06.018","article-title":"Inclisiran durably lowers LDL-C and PCSK9 expression in subjects with homozygous familial hypercholesterolaemia: the Orion-2 Pilot Study","volume":"287","author":"Raal","year":"2019","journal-title":"Atherosclerosis"},{"key":"R32-20230917","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11883-016-0579-0","article-title":"Recent developments in gene therapy for homozygous familial hypercholesterolemia","volume":"18","author":"Ajufo","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jmedgenet-2018-105713","article-title":"Review of the scientific evolution of gene therapy for the treatment of homozygous familial hypercholesterolaemia: past, present and future perspectives","volume":"56","author":"Rodriguez-Calvo","year":"2019","journal-title":"J Med Genet"},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fimmu.2014.00350","article-title":"Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions","volume":"5","author":"Basner-Tschakarjan","year":"2014","journal-title":"Front Immunol"},{"key":"R36-20230917","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"R37-20230917","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1089\/hum.2018.014","article-title":"Results at 5 years after gene therapy for RPE65-deficient retinal dystrophy","volume":"29","author":"Pennesi","year":"2018","journal-title":"Hum Gene Ther"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2217\/pme-2018-0155","article-title":"The clinical application of gene editing: ethical and social issues","volume":"16","author":"Ormond","year":"2019","journal-title":"Per Med Future"},{"key":"R43-20230917","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ajhg.2017.06.012","article-title":"Human germline genome editing","volume":"101","author":"Ormond","year":"2017","journal-title":"Am J Hum Genet"},{"key":"R44-20230917","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.119.042476","article-title":"In vivo AAV-CRISPR\/Cas9-mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia","volume":"141","author":"Zhao","year":"2020","journal-title":"Circulation"},{"key":"R45-20230917","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","article-title":"Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3","volume":"137","author":"Chadwick","year":"2018","journal-title":"Circulation"},{"key":"R46-20230917","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1038\/s41598-019-41056-w","article-title":"Function and immunogenicity of gene-corrected iPSC-derived hepatocyte-like cells in restoring low density lipoprotein uptake in homozygous familial hypercholesterolemia","volume":"9","author":"Okada","year":"2019","journal-title":"Sci Rep"},{"key":"R47-20230917","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep4.1110","article-title":"CRISPR correction of a homozygous low-density lipoprotein receptor mutation in familial hypercholesterolemia induced pluripotent stem cells","volume":"1","author":"Omer","year":"2017","journal-title":"Hepatol Commun"},{"key":"R48-20230917","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.042911","article-title":"Familial hypercholesterolemia class II low density lipoprotein-receptor response to statin treatment","author":"Omer","year":"2020","journal-title":"Dis Model Mech"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T08:02:12Z","timestamp":1694937732000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000677","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}